Infinitopes Achieves Major Financing Milestone
Infinitopes, a pioneering biotechnology firm specializing in cancer vaccines, announced today the successful conclusion of its seed financing round, securing a total of $35.1 million. This remarkable achievement marks a significant step in the company's mission to enhance treatment options for cancers, particularly oesophageal cancer.
Details of the Financing Round
The recent financing was co-led by Octopus Ventures along with the newly added investor, Amplify Bio. Additional funds came from Macmillan Cancer Support, a new participant in this round, while existing investors such as Cancer Research Horizons and Manta Ray Ventures also played a crucial role. This influx of capital fortifies the company's financial position as it prepares to embark on its first-in-human clinical trial.
Launching Clinical Trials for ITOP1
With the new funding, Infinitopes is gearing up for its double-blind, randomized, placebo-controlled clinical trial of ITOP1, its lead candidate aimed at preventing the recurrence of oesophageal cancer. This critical therapy is being developed in response to a major clinical need, as existing treatments often fall short in addressing this aggressive form of cancer. The upcoming Phase I/IIa VISTA trial will be conducted at various NHS university cancer centers across the UK, reinforcing Infinitopes' reputation as an innovator in the sector.
Leadership Insights on the Trial
Jonathan Kwok, the Chief Executive Officer of Infinitopes, expressed excitement about the partnership with Amplify Bio and Macmillan, stating, "I’m honoured to welcome leading US West Coast biofund Amplify Bio and ecosystem champions for better patient care, Macmillan, onto our cap table. This new funding unlocks our potentially groundbreaking Phase I/IIa trial, enabling proof-of-concept evaluation of Infinitopes' AI/ML-precision targeted, off-the-shelf vaccine platform to prevent recurrence after surgical resection. We aim to lead the development of innovative medicines that bring hope to patients suffering from cancers with unmet medical needs. We anticipate sharing our early findings at major conferences later this year."
Expert Perspective on Cancer Vaccines
Elliot Hershberg, Partner at Amplify Bio, emphasized the timely relevance of cancer vaccines, saying, "Recent clinical evidence has made it abundantly clear that the time for cancer vaccines is now. After years of searching, Infinitopes has clearly distinguished itself as the company positioned to drive this progress forward. The combination of rigorous AI-powered immunomics profiling, a highly scalable off-the-shelf vector, and a defined clinical strategy is exactly what this field needs. Infinitopes has the potential to redefine immunotherapy and precision oncology in the years to come."
About Infinitopes and Its Innovative Programs
Infinitopes Ltd is recognized as a clinical-stage cancer biotechnology firm supported by Cancer Research UK and the esteemed University of Oxford. The company's strategy revolves around leveraging groundbreaking platforms in precision target discovery alongside high-efficiency vector delivery systems. Their goal is to develop resilient vaccines against various solid tumor indications. Lead candidate ITOP1 is anticipated to commence Phase I/IIa trials in the near future, following the approval of necessary regulatory submissions.
Since its inception, Infinitopes has attracted significant talent specializing in areas such as antigen discovery, immunology, and regulatory affairs. The company has been awarded the 'Innovative Licensing and Access Pathway' innovation passport from the MHRA. Additionally, Infinitopes has secured substantial non-dilutive funding from Innovate UK, reflecting the growing confidence in its innovative approaches to cancer treatment.
Conclusion and Future Prospects
The funds raised by Infinitopes mark a decisive moment in the pursuit of groundbreaking advancements in cancer care. The company’s objective is to lead the charge in transforming how we consider cancer treatment, with a strong focus on fulfilling unmet medical needs. As they prepare for clinical trials and further innovations, Infinitopes continues to stand at the forefront of the fight against cancer.
Frequently Asked Questions
What is Infinitopes?
Infinitopes is a biotechnology company that focuses on developing cancer vaccines to improve treatment for various forms of cancer.
How much funding did Infinitopes secure?
Infinitopes successfully raised $35.1 million through its recent seed financing round.
What is the purpose of the ITOP1 vaccine?
The ITOP1 vaccine is designed to prevent the recurrence of oesophageal cancer. It is currently preparing for its first clinical trial.
Who are the investors in Infinitopes?
The recent funding round was co-led by Octopus Ventures and Amplify Bio, with additional investments from Macmillan Cancer Support and others.
Where will the clinical trials for ITOP1 take place?
The clinical trials for ITOP1 will be conducted across multiple NHS university cancer centers in the UK.
